← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	126 Genenta Science GNTA $31.8M	–	–	–	–
127	127 GRAIL Inc GRAL $5.46B	–	–	–	–
128	GRCL 128 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
129	GRML 129 Greenland Mines Ltd GRML $87.2M	–	–	–	–
130	GTH 130 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
131	131 Fractyl Health GUTS $25.5M	–	–	–	–
132	132 Franklin Genomic Advancements ETF HELX $28.9M	–	–	–	–
133	133 iShares Genomics Immunology and Healthcare ETF IDNA $306M	–	–	–	–
134	134 Immix Biopharma IMMX $676M	–	–	–	–
135	135 Immatics IMTX $1.03B	–	–	–	–
136	136 IN8bio INAB $11.6M	–	–	–	–
137	137 MiNK Therapeutics INKT $49M	–	–	–	–
138	138 INmune Bio INMB $44.7M	–	–	–	–
139	139 Century Therapeutics IPSC $264M	–	–	–	–
140	KRBP 140 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
141	141 Korro Bio KRRO $133M	–	–	–	–
142	142 Kyverna Therapeutics KYTX $359M	–	–	–	–
143	143 Legend Biotech LEGN $3.65B	–	–	–	–
144	LGVN 144 Longeveron LGVN $4.5M	–	–	–	–
145	145 Lunai Bioworks LNAI $3.6M	–	–	–	–
146	LOGC 146 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	–	–	–	–
147	147 Lexeo Therapeutics LXEO $231M	–	–	–	–
148	148 Lyell Immunopharma LYEL $203M	–	–	–	–
149	149 DELISTED 23andMe Holding Co ME	–	–	–	–
150	150 MeiraGTx Holdings MGTX $899M	–	–	–	–